CWT-001 is under clinical development by Causeway Therapeutics and currently in Phase I for Lateral Epicondylitis(Tennis Elbow). According to GlobalData, Phase I drugs for Lateral Epicondylitis(Tennis Elbow) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CWT-001 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Causeway Therapeutics overview
Causeway Therapeutics., is engaged in development of therapy for tendon problems. The company is headquartered in United Kingdom.
For a complete picture of CWT-001’s drug-specific PTSR and LoA scores, buy the report here.